Reich A, Lis-Święty A, Krasowska D, Maj J, Narbutt J, Sysa-Jedrzejowska A, Wojas-Pelc A, Woźniacka A, Rudnicka L (2021) Dermatomyositis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatology Review/Przegląd Dermatologiczny 108:85–104. https://doi.org/10.5114/dr.2021.107278
CAS
Article
Google Scholar
Didona D, Juratli HA, Scarsella L, Eming R, Hertl M (2020) The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol 30:229–242. https://doi.org/10.1684/ejd.2020.3761
CAS
Article
PubMed
Google Scholar
DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267–281. https://doi.org/10.1016/j.jaad.2019.06.1309
CAS
Article
PubMed
Google Scholar
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O’Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
Article
PubMed
Google Scholar
Thompson C, Piguet V, Choy E (2018) The pathogenesis of dermatomyositis. Br J Dermatol 179:1256–1262. https://doi.org/10.1111/bjd.15607
CAS
Article
PubMed
Google Scholar
Casal Dominguez M, Pinal-Fernandez I, Mammen A (2021) Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence. Current Treatment Options in Rheumatology. https://doi.org/10.1007/s40674-021-00182-1
Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345–1349. https://doi.org/10.1136/ard.2006.068502
Article
PubMed
PubMed Central
Google Scholar
Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48–55. https://doi.org/10.1016/j.jaut.2019.04.001
CAS
Article
PubMed
PubMed Central
Google Scholar
Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ (2017) Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 84:55–64. https://doi.org/10.1016/j.jaut.2017.06.007
CAS
Article
PubMed
PubMed Central
Google Scholar
Wolstencroft PW, Fiorentino DF (2018) Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep 20:28. https://doi.org/10.1007/s11926-018-0733-5
Article
PubMed
Google Scholar
Casal-Dominguez M, Pinal-Fernandez I, Pak K, Huang W, Selva-O’Callaghan A, Albayda J, Casciola-Rosen L, Paik JJ, Tiniakou E, Mecoli CA, Lloyd TE, Danoff SK, Christopher-Stine L, Mammen AL (2021) Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis Rheumatol. https://doi.org/10.1002/art.41964
Article
PubMed
Google Scholar
Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23. https://doi.org/10.1111/joim.12451
CAS
Article
PubMed
Google Scholar
McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14:290–302. https://doi.org/10.1038/nrrheum.2018.56
CAS
Article
PubMed
Google Scholar
Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N (2018) Dermatomyositis: current concepts. Clin Dermatol 36:450–458. https://doi.org/10.1016/j.clindermatol.2018.04.003
Article
PubMed
Google Scholar
Hodgkinson LM, Wu TT, Fiorentino DF (2021) Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med 9:433. https://doi.org/10.21037/atm-20-5175
CAS
Article
PubMed
PubMed Central
Google Scholar
Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46:565–576. https://doi.org/10.1016/j.rdc.2020.05.006
Article
PubMed
Google Scholar
Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21:131–136. https://doi.org/10.1177/1203475416665601
Article
PubMed
Google Scholar
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1–19. https://doi.org/10.1007/s12016-015-8510-y
CAS
Article
PubMed
PubMed Central
Google Scholar
Stertz O (1916) Polymyositis. Berl. Klin Wochenschr 53:489
Google Scholar
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095. https://doi.org/10.7326/0003-4819-134-12-200106190-00008
CAS
Article
PubMed
Google Scholar
Hsu J-L, Liao M-F, Chu C-C, Kuo H-C, Lyu R-K, Chang H-S, Chen C-M, Wu Y-R, Chang K-H, Weng Y-C, Chang C-W, Chiang H-I, Cheng C-K, Lee P-W, Huang C-C, Ro L-S (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep 11:4545. https://doi.org/10.1038/s41598-021-83729-5
CAS
Article
PubMed
PubMed Central
Google Scholar
Olazagasti JM, Baez PJ, Wetter DA, Ernste FC (2015) Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 16:89–98. https://doi.org/10.1007/s40257-015-0120-1
Article
PubMed
Google Scholar
Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore) 97:e9639. https://doi.org/10.1097/md.0000000000009639
Article
Google Scholar
Hsu J-L, Liao M-F, Chu C-C, Kuo H-C, Lyu R-K, Chang H-S, Chen C-M, Wu Y-R, Chang K-H, Weng Y-C, Chang C-W, Chiang H-I, Cheng C-K, Lee P-W, Huang C-C, Ro L-S (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. https://doi.org/10.1038/s41598-021-83729-5
Article
PubMed
PubMed Central
Google Scholar
Teoh JW, Yunus RM, Hassan F, Ghazali N, Abidin ZA (2014) Nasopharyngeal carcinoma in dermatomyositis patients: a 10-year retrospective review in Hospital Selayang, Malaysia. Rep Pract Oncol Radiother 19:332–336. https://doi.org/10.1016/j.rpor.2014.02.005
CAS
Article
PubMed
PubMed Central
Google Scholar
Morris P, Dare J (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32:189–191. https://doi.org/10.1097/MPH.0b013e3181bf29a2
Article
PubMed
Google Scholar
Khanna U, Galimberti F, Li Y, Fernandez AP (2020) Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Ann Transl Med 9:432
Article
Google Scholar
Szekanecz E, András C, Sándor Z, Antal-Szalmás P, Szántó J, Tamási L, Kiss E, Szekanecz Z (2006) Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 6:42–47. https://doi.org/10.1016/j.autrev.2006.03.007
Article
PubMed
Google Scholar
Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67:317–326. https://doi.org/10.1002/art.38928
CAS
Article
PubMed
PubMed Central
Google Scholar
Vlagea A, Falagan S, Gutiérrez-Gutiérrez G, Moreno-Rubio J, Merino M, Zambrana F, Casado E, Sereno M (2018) Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol 127:42–49. https://doi.org/10.1016/j.critrevonc.2018.05.002
Article
PubMed
Google Scholar
Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:3682–3689. https://doi.org/10.1002/art.22164
CAS
Article
PubMed
Google Scholar
Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46:25–28. https://doi.org/10.1093/rheumatology/kel161
CAS
Article
Google Scholar
Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522. https://doi.org/10.1002/art.33403
CAS
Article
PubMed
Google Scholar
McAvera RM, Crawford LJ (2020) TIF1 proteins in genome stability and cancer. Cancers (Basel) 12. https://doi.org/10.3390/cancers12082094
Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353. https://doi.org/10.1007/s40257-020-00502-6
Article
PubMed
Google Scholar
Casal-Dominguez M, Pinal-Fernandez I, Mego M, Accarino A, Jubany L, Azpiroz F, Selva-O’callaghan A (2017) High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve 56:386–392. https://doi.org/10.1002/mus.25507
CAS
Article
PubMed
Google Scholar
Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72:449–455. https://doi.org/10.1016/j.jaad.2014.12.009
Article
PubMed
PubMed Central
Google Scholar
De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E (2020) Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford) 59:469–477. https://doi.org/10.1093/rheumatology/kez572
CAS
Article
Google Scholar
Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65:2954–2962. https://doi.org/10.1002/art.38093
CAS
Article
PubMed
PubMed Central
Google Scholar
Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D (2019) Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99:256–262. https://doi.org/10.2340/00015555-3091
CAS
Article
PubMed
Google Scholar
Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58:650–655. https://doi.org/10.1093/rheumatology/key357
Article
Google Scholar
Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M (2020) Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis. J Dermatol 47:490–496. https://doi.org/10.1111/1346-8138.15284
CAS
Article
PubMed
Google Scholar
Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M (2018) Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients. Clin Exp Rheumatol 36:990–995
PubMed
Google Scholar
Espada G, MALDONADO COCCO JA, FERTIG N, ODDIS CV, (2009) Clinical and serologic characterization of an argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36:2547–2551. https://doi.org/10.3899/jrheum.090461
CAS
Article
PubMed
Google Scholar
Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Zinn AR, Shime H, Inoue N (2007) Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 18:1701–1709. https://doi.org/10.1091/mbc.e06-08-0747
CAS
Article
PubMed
PubMed Central
Google Scholar
Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1771–1776. https://doi.org/10.1002/acr.23188
CAS
Article
Google Scholar
Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1909–1914. https://doi.org/10.1002/acr.23210
CAS
Article
Google Scholar
Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710–713. https://doi.org/10.1136/annrheumdis-2011-200697
CAS
Article
PubMed
Google Scholar
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132–3137. https://doi.org/10.1002/art.22862
CAS
Article
PubMed
Google Scholar
Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68:1621–1625. https://doi.org/10.1136/ard.2008.097162
CAS
Article
PubMed
Google Scholar
Muro Y, Sugiura K, Nara M, Sakamoto I, Suzuki N, Akiyama M (2015) High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis. Rheumatology (Oxford) 54:1745–1747. https://doi.org/10.1093/rheumatology/kev247
Article
Google Scholar
Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A (2012) Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384:128–134. https://doi.org/10.1016/j.jim.2012.07.019
CAS
Article
PubMed
Google Scholar
Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, Yamaoka T, Fujikawa K, Tsukada T, Sato K, Echigo T, Hasegawa M, Takehara K (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72:151–153. https://doi.org/10.1136/annrheumdis-2012-201736
Article
PubMed
Google Scholar
Albayda J, Mecoli C, Casciola-Rosen L, Danoff SK, Lin CT, Hines D, Gutierrez-Alamillo L, Paik JJ, Tiniakou E, Mammen AL, Christopher-Stine L (2021) A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol 3:287–294. https://doi.org/10.1002/acr2.11247
Article
PubMed
PubMed Central
Google Scholar
Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, Kuwana M (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLOS One 8:e60442. https://doi.org/10.1371/journal.pone.0060442
Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65:242–245. https://doi.org/10.1136/ard.2005.040717
CAS
Article
PubMed
PubMed Central
Google Scholar
Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I, Franceschini F, Cantarini L, Satoh M, Selmi C (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36:469–475. https://doi.org/10.1007/s10067-016-3453-0
Article
PubMed
Google Scholar
Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, Lester S (2015) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52:196–203. https://doi.org/10.1002/mus.24541
CAS
Article
PubMed
Google Scholar
Molina-Ruiz AM, Romero F, Carrasco L, Feltes F, Haro R, Requena L (2015) Amyophatic dermatomyositis presenting as a flagellated skin eruption with positive MDA5 antibodies and thyroid cancer: a real association? Clin Exp Dermatol 40:887–890. https://doi.org/10.1111/ced.12674
CAS
Article
PubMed
Google Scholar
Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275–285. https://doi.org/10.1007/s11926-012-0249-3
CAS
Article
PubMed
Google Scholar